Current status of clinical researches on metastatic triple negative breast cancer
10.3760/cma.j.issn.1673-422X.2020.03.008
- VernacularTitle:转移性三阴性乳腺癌临床研究现状
- Author:
Kaichun LI
1
;
Yajie WANG
Author Information
1. 同济大学附属上海市第四人民医院肿瘤科 200081
- From:
Journal of International Oncology
2020;47(3):169-173
- CountryChina
- Language:Chinese
-
Abstract:
Triple negative breast cancer (TNBC) is associated with a high risk of recurrence and generally a poor prognosis. Median survival time of metastatic triple negative breast cancer (mTNBC) is about one year. Currently, the mainstay of treatment for mTNBC remains cytotoxic chemotherapy. In recent years, the drugs involved in the clinical researches of mTNBC include poly-ADP-ribose polymerase inhibitors, phosphoinositide 3-kinase pathway inhibitors, antibody targeting epidermal growth factor receptor, antibody targeting trophoblast surface antigen-2, antibody targeting death receptor 5, endocrine therapy drugs for androgen receptor, and immune checkpoint inhibitors and so on. New drugs have gradually improved the survival of patients with mTNBC.
